J. L. Bainbridge & Co. Inc. Cuts Position in Eli Lilly and Company (NYSE:LLY)

J. L. Bainbridge & Co. Inc. reduced its position in Eli Lilly and Company (NYSE:LLY) by 84.8% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 523 shares of the company’s stock after selling 2,907 shares during the quarter. J. L. Bainbridge & Co. Inc.’s holdings in Eli Lilly and Company were worth $404,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Buckley Wealth Management LLC grew its stake in Eli Lilly and Company by 3.6% during the 4th quarter. Buckley Wealth Management LLC now owns 546 shares of the company’s stock valued at $422,000 after purchasing an additional 19 shares during the last quarter. United Capital Management of KS Inc. lifted its holdings in Eli Lilly and Company by 0.7% during the fourth quarter. United Capital Management of KS Inc. now owns 12,317 shares of the company’s stock valued at $9,509,000 after purchasing an additional 84 shares in the last quarter. Associated Banc Corp boosted its holdings in Eli Lilly and Company by 95.5% in the 4th quarter. Associated Banc Corp now owns 51,403 shares of the company’s stock worth $39,683,000 after buying an additional 25,104 shares during the last quarter. HMV Wealth Advisors LLC acquired a new stake in shares of Eli Lilly and Company in the fourth quarter worth approximately $1,238,000. Finally, First National Trust Co grew its holdings in shares of Eli Lilly and Company by 10.0% during the fourth quarter. First National Trust Co now owns 34,035 shares of the company’s stock worth $26,275,000 after buying an additional 3,096 shares in the last quarter. 82.53% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of equities analysts recently commented on LLY shares. Morgan Stanley set a $1,146.00 price objective on Eli Lilly and Company in a research report on Thursday, March 6th. Citigroup decreased their price target on shares of Eli Lilly and Company from $1,250.00 to $1,190.00 and set a “buy” rating for the company in a research report on Tuesday, January 28th. Truist Financial lifted their price objective on Eli Lilly and Company from $1,029.00 to $1,038.00 and gave the company a “buy” rating in a research note on Monday, February 3rd. StockNews.com raised Eli Lilly and Company from a “hold” rating to a “buy” rating in a report on Friday, February 7th. Finally, Wells Fargo & Company upped their target price on shares of Eli Lilly and Company from $970.00 to $1,100.00 and gave the company an “overweight” rating in a report on Wednesday, March 5th. Three equities research analysts have rated the stock with a hold rating and eighteen have given a buy rating to the company’s stock. According to data from MarketBeat, Eli Lilly and Company currently has a consensus rating of “Moderate Buy” and an average target price of $1,009.72.

Eli Lilly and Company Trading Up 1.5 %

NYSE LLY opened at $813.55 on Friday. The company has a quick ratio of 0.97, a current ratio of 1.15 and a debt-to-equity ratio of 2.00. The stock has a market capitalization of $771.38 billion, a P/E ratio of 69.47, a P/E/G ratio of 1.40 and a beta of 0.34. Eli Lilly and Company has a 52-week low of $711.40 and a 52-week high of $972.53. The firm has a 50-day moving average price of $830.81 and a 200 day moving average price of $844.01.

Eli Lilly and Company (NYSE:LLY) last issued its earnings results on Thursday, February 6th. The company reported $5.32 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $5.45 by ($0.13). Eli Lilly and Company had a return on equity of 85.24% and a net margin of 23.51%. Equities research analysts expect that Eli Lilly and Company will post 23.48 EPS for the current year.

Eli Lilly and Company announced that its board has initiated a share buyback plan on Monday, December 9th that authorizes the company to buyback $15.00 billion in shares. This buyback authorization authorizes the company to repurchase up to 2% of its stock through open market purchases. Stock buyback plans are generally an indication that the company’s management believes its shares are undervalued.

Insider Buying and Selling at Eli Lilly and Company

In other news, CAO Donald A. Zakrowski sold 1,000 shares of the stock in a transaction dated Thursday, March 13th. The shares were sold at an average price of $818.24, for a total value of $818,240.00. Following the completion of the transaction, the chief accounting officer now owns 5,840 shares in the company, valued at $4,778,521.60. This trade represents a 14.62 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. 0.13% of the stock is owned by corporate insiders.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.